QBKPN SSI

BIOLOGICAL2 trials

Sponsors

Qu Biologics Inc.

Conditions

Immune DeficiencyNon-Small Cell Lung Cancer

Phase 2

Exploratory Study of QBKPN SSI in Non-Small Cell Lung Cancer

CompletedNCT02256852

Qu Biologics Inc.Non-Small Cell Lung Cancer

Start: 2014-12-31End: 2015-11-30Updated: 2016-02-22

Efficacy of QBKPN Site-Specific Immunomodulator in Improving Innate Immune Function & Reducing Respiratory Tract Infection in Older Adults

RecruitingNCT05421325

Qu Biologics Inc.Immune Deficiency

Start: 2023-04-11End: 2026-02-28Target: 72Updated: 2025-01-22

Related Papers

Site-Specific Immunomodulators (SSIs) are novel immunotherapies for cancer

The Journal of Immunology2016-05-01